ArticleScientific reports2025
Stability-indicating spectrophotometric quantification of safinamide in the presence of its possible degradation product.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent times, a truly exquisite pharmaceutical marvel has graced the world of medicine, known as Safinamide (SAF). This opulent creation has been specifically tailored to cater to the needs of individuals afflicted with Parkinson's disease (PD), an esteemed neurological condition renowned for its regal ability to impede motor skills, coordination, and equilibrium. It is highly improbable that degradation products of pharmaceutical components would significantly compromise efficiency and safety of a drug during its shelf life. Pharmaceutical analysis requires a variety of stability tests to be conducted under distinct conditions. As a result, there was an increased need for the development of an analytical methodology capable of reliably separating and quantifying degradants and impurities that might be found in pharmaceuticals. In this study, we have developed two efficient and straightforward spectrophotometric methodologies for the concurrent estimation of SAF and its degradation product (SAF DEG), which is the main acid hydrolysis product. The confirmation of degradation product build-up by the use of several analytical techniques, including infrared spectroscopy (IR), and mass spectrometry (MS) investigations. The present methodologies have been validated for linearity within the concentration range of 5-30 µg/ml for SAF, and 5-15 µg/mL, 2-15 µg/ml for SAF DEG for fourier self-deconvolution (FSD) and dual wavelength (DW) methods, respectively. The originality of these techniques lies in their status as the first stability-indicating spectrophotometric procedures that are both environmentally friendly. Moreover, the process of obtaining pure SAF DEG offers substantial economic benefits by obviating the need to acquire a costly constituent. The use of intelligent techniques was employed to analyze the pharmaceutical dosage form, potentially offering significant advantages to the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.